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Uroplakins in the Lower Urinary Tract
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The apical surface of mammalian urinary epithelium is covered by numerous scallop-shaped membrane plaques. This plaque 
consists of four different uroplakins (UPs) and integral membrane proteins. UPs, which are a member of the tetraspanin super-
family, are assembled into plaques that act as an exceptional barrier to water and toxic materials in urine. Within the plaques, the 
four UPs are organized into two heterodimers consisting of UP Ia/UP II and UP Ib/UP III in the endoplasmic reticulum. The 
two heterodimers bind to a heterotetramer, and then assemble into 16-nm particles in the Golgi apparatus. The aggregated UP 
complex ultimately covers almost all the mature fusiform vesicles in cytoplasm. These organelles migrate towards the apical uro-
thelial cells, where they can fuse with the apical plasma membrane. As a result, the UPs are synthesized in large quantities only 
by terminally differentiated urothelial cells. For this reason, the UPs can be regarded as a major urothelial differentiation marker. 
In UP knockout (KO) mice, the incorporation of fully assembled UP plaques in cytoplasm into the apical surface is not function-
al. The mice with UP III-deficient urothelium show a significantly reduced number of UPs, whereas those with UP II-deficient 
urothelium have nearly undetectable levels of UPs. This finding strongly suggests that UP II ablation completely abolishes plaque 
formation. In addition, UP II KO mice contain abnormal epithelial polyps or complete epithelial occlusion in their ureters. UP 
IIIa KO mice are also associated with impairment of the urothelial permeability barrier and development of vesicoureteral reﬂux 
as well as a decrease in urothelial plaque size. In this review, I summarize recently published studies about UPs and attempt to 
explain the clinical significance of our laboratory results.
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Because the kidney filters plasma and excretes the wastes into 
the urine, urine differs markedly from plasma in osmolality and 
acidity. The urinary bladder in mammals stores highly perme-
able molecules such as urea, ammonia, and water to prevent 
them from crossing the bladder mucosa for prolonged periods 
without disturbance [1-3]. The mechanism of a permeable bar-
rier has been suggested for these reasons. Sun et al. [3-7] report-
ed that the apical membrane of urinary bladder contains a group 
of four related transmembrane (TM) proteins, called uroplakins 
(UPs), that act an exceptional barrier to water, small non-elec-
trolytes, and protons. The asymmetric unit membrane (AUM), 
which can be seen by electron microscopy, forms the apical 
plaques of mammalian urothelium [3,8]. The AUM consists of 
the numerous assembly of four UPs: Ia, Ib, II, and III [4-7]. The 
UPs are believed to play a role in homeostasis in the urinary 
bladder mucosa during contraction and relaxation, preventing 
the AUM from rupturing during bladder distension [9-11]. 
  When this permeability barrier is breached, irritants in the 
urine reach the bladder submucosa structure, musculature, and 
nociceptive nerve endings. The inflamed nociceptor fibers can 
ignite an abnormal sensory circuit and the injured muscular 
structures lead to urinary frequency, urgency, and painful void-
ing syndrome [12,13]. Furthermore, long-lasting breaches in 
the bladder permeability barrier may lead to dysplasia of tumor 
growth, interstitial cystitis, and non-bacterial chronic cystitis 
[13,14]. 
  Although extensive studies have been conducted over the 
past two decades on the pathophysiology of voiding dysfunc-
tion, little research has been carried out on the role of UPs in 
the urinary bladder. This review will summarize the genetic 
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characteristics and significance of UPs in the field of transla-
tional research. 
GENETIC CHARACTERISTICS OF UROPLAKINS
The AUM contains four uroplakins: UP Ia, UP Ib, UP II, and 
UP III (UP IIIa and UP IIIb) (Fig. 1). The mammalian UPs, in-
cluding bovine, human, and mouse, are highly conserved [15]. 
Many tetraspanins such as UP Ia and Ib interact with important 
single TM domain signaling partner proteins [16,17]. As can be 
inferred from the name, the tetraspanin superfamily contains 
four TM domains (Fig. 2) [17]. The tetraspanin superfamily 
usually contains several conserved amino acid residues in ami-
no acid sequences, which suggests that these UPs may play im-
portant roles in cell migration, immunologic signaling, infec-
tion, and membrane architecture [18,19]. However, UP II and 
UP III have only a single TM domain and share a stretch of 12 
amino acid residues located on the extracellular side of the sin-
gle TM domain (RT/SGGMV/IVITV/SL/IL) (Fig. 3) [20]. Of 
these four major UPs, UP IIIa is the only one that has a relative-
ly large cytoplasmic domain of 50 amino acid residues, which 
has been postulated to play a role in interacting with the cyto-
skeleton (Fig. 3) [4,20,21].
  The sequence of UP IIIb is related to that of UP IIIa, and they 
also have six similar exons and share conserved sequences such 
as IDTWPGRRSC/GMIVITSIL in the extracellular side of the 
TM domain, which suggests that the conserved area plays an 
active role for interacting with other important proteins (Fig. 4). 
UP II is synthesized as a pre (26 amino acids)–pro (59 amino 
acids)–mature protein (100 amino acids); the mature UP II (15-
kDa) can be divided into a long extracellular domain of 71 ami-
no acids and a TM domain of 25 amino acids, with almost no 
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Fig. 1. The functional units of mouse uropla  kins (UPs) are en-
coded by separate genes on different chromosomes. The mam-
malian UPs, including bovine, human, rat, and mouse, are 
highly conserved. 
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Fig. 2. Molecular structures of tetraspanins. Many tetraspanins 
such as uroplakin Ia, and Ib are typically composed of 4 trans-
membrane (TM) domains containing several conserved amino 
acid sequences (Modified from Levy S and Shoham T. Physiolo-
gy (Bethesda) 2005;20:218-24, with permission American 
Physiological Society) [17]. 
Fig. 3. The mouse uroplakin (UP) II and UP IIIa have a single 
transmembrane (TM) domain and share a conserved 12 amino 
acid residues located on the extracellular side and the TM do-
main (RT/SGGMV/IVITV/SL/IL). Interestingly, UP IIIa is the 
only UP that has a relatively large cytoplasmic domain of 50 
amino acid residues. (Modified from Sun TT. Am J Physiol Re-
nal Physiol 2006;291:F9-21, with permis  sion of American Phys-
iological Society) [20].
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Fig. 4. The mouse uroplakin IIIa and IIIb have 6 exonal struc-
tures. The amino acid residues from rat and human uroplakin 
IIIa and IIIb also share conserved amino acid sequences. 
52               156                   280                   83               133                       160 mUP IIIa
Exon I           Exon II                           Exon III                   Exon IV              Exon V                        Exon VI
mUP IIIb 85                 150                  306                    80               130                       160
mUP IIIa
Exon I Exon II Exon III Exon IV Exon V Exon VI
mUP IIIb
52 156 280 83 133 160
85 150 306 80 130 1606    www.einj.org
Lee  •  Uroplakins in the Lower Urinary Tract
doi: 10.5213/inj.2011.15.1.4
INJ
intracellular domain [4]. UP IIIa is synthesized as a pre-protein; 
the mature protein (47-kDa) contains an apoprotein of 29-kDa 
plus 18-kDa equivalents of complex glycans [21]. 
MORPHOLOGY OF UPS
The structure of the urothelial plaque has been studied by using 
a number of ultrastructural techniques, including atomic force 
microscopy, quick-freeze deep-etch, and cryo-electron micros-
copy [8,22,23]. Such data have shown that the apical surface of 
the mammalian urinary bladder epithelium is covered by nu-
merous scallop-shaped membrane plaques (Fig. 5). The plaque 
has a unique structure in which its outer leaﬂet is about twice as 
thick as the inner one, hence, the name asymmetric unit mem-
brane [24]. The AUM contains four different UPs and integral 
membrane proteins that assemble into hexagonal plaque parti-
cles [20]. 
  Within each UP pair (UP Ia/II and UP Ib/IIIa), there are a 
total of ﬁve TM domains (four TMs for UP Ia and UP Ib, and 
one TM for UP II and UP III) [25,26]. The ﬁve TM helices of 
each heterodimer are tightly packed, forming six inner-domains 
and six outer-domains. Furthermore, UPs stabilize a particularly 
rigid set of lipids within the outer leaﬂet in the AUM [22]. 
  The AUM structure is also present in fusiform-shaped cyto-
plasmic vesicles representing a pre-apical membrane compart-
ment. These fusiform-shaped cytoplasmic vesicles create a con-
cave or scallop-shaped plaque in the apical membrane or in ter-
minally differentiated urothelial (umbrella) cells [11,20,27]. 
FUNCTIONS OF UPS
The amino acid sequences of mammalian UPs are highly con-
served, which suggests that they play an essential function in 
urinary bladder epithelium [1,2,15,16]. This highly specialized 
membrane is believed to serve as an exceptionally effective per-
meability barrier [1-3], as a mechanical anchorage site mediat-
ing binding of the cytoskeleton to the apical membrane surface 
[8,5], and as a mechanism for adjusting the apical surface area 
through the reversible insertion and retrieval of the apical plaques 
[10,11,27,28]. Furthermore, urothelial plaques are biochemical-
ly unique. These membranes are unusually stable in that they 
remain insoluble in a number of harsh conditions including 2% 
NP-40, 2% sodium sarcosine, 25 mM NaOH, 9 M urea, and 6 
M guanidiumchloride [2].
  In normal urothelium, differentiated superficial cells gradu-
ally develop from basal and intermediate cells. Because urothe-
lial plaques and their protein subunits, i.e., the UPs, are synthe-
sized in large quantities only by terminally differentiated uro-
thelial cells, the UPs are regarded as a major urothelial differen-
tiation marker [29]. In addition, recent studies indicate that UP 
Ia may serve as the urothelial receptor for type 1-ﬁmbriated 
Escherichia coli, which causes 90% of urinary tract infections 
[30]. UP Ia is only expressed in mouse ventral prostate. This 
suggests that the mouse ventral prostate may be an adequate lo-
cus for acute or chronic bacterial prostatitis study (Fig. 6) [31].
  The presence of UP Ib in the ocular surface and respiratory 
epithelia suggests that UP Ib may play a unique biological role 
in these tissues (Table 1). 
Fig. 5. Scanning electron microscopic images of normal mouse 
urinary bladder. The mouse urinary bladder epithelium is cov-
ered by numerous scallop-shaped membrane plaques. 
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Fig. 6. Uroplakin and β-actin expression on urinary bladder 
and prostate. Bladder, urinary bladder; VP, ventral prostate; PLP, 
posterior lateral prostate; Coagulating, coagulating gland (Re-
printed from Lee DH and Lee GH. Korean J Androl 2010;28: 
112-7, with permis  sion of Korean Society for Sexual Medicine 
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TRAFFICKING
The mechanisms underlying the dynamic changes in the apical 
membrane compartment are unclear. Discoid vesicles may pro-
vide the bladder with a large membrane reserve to adapt to 
changes in urine volume and to immediately substitute leaky 
membrane areas. Fusion of the discoid vesicles with the apical 
plasma membrane results in an increase in the surface mem-
brane area, which might be useful during filling of the bladder 
when the urothelium has to stretch [11,20,32,33]. 
  The UPs undergo an assembly process that begins in the en-
doplasmic reticulum (ER) where they form speciﬁc heterodi-
mers [20,25,26,34]. Recent studies indicate that UP Ia and UP 
Ib bind to UP II and UP IIIa, respectively, forming the heterodi-
mers Ia/II and Ib/IIIa before they can exit from the ER [16,26, 
34]. UP Ib is exceptional because it can exit, by itself, from the 
ER [26].  
  Severs and Hicks [35] have shown that, in normal urotheli-
um, 16-nm particles can be detected in early vesicles that have 
just budded off the Golgi apparatus, which suggests that the 
two UP heterodimers (Ia/II and Ib/III) interact before they leave 
the Golgi apparatus to form the 16-nm particle. These data sug-
gest that UPs first form heterodimers in the ER [26], and possi-
bly heterotetramers; the heterotetramers then assemble into the 
16-nm particles in the Golgi apparatus or the trans-Golgi net-
work. Then, these particles, once reaching a sufficient density in 
the post-Golgi vesicles, aggregate to form small, and later, large 
2D crystals. In a post-Golgi compartment they form increas-
ingly larger crystalline arrays [8,28], which ultimately cover al-
most the entire surface of the mature fusiform vesicles. These 
organelles migrate toward the apical cell periphery where they 
can fuse with the apical plasma membrane [10,32,33].
  Although UP Ia is transported to the plasma membrane only 
after heterodimerization with UPII, UP Ib is unique in that it 
can exit from the ER and move to the plasma membrane even 
when expressed by itself at the surface of urothelial cells of UP 
IIIa-knockout (KO) mice [26]. On the other hand, in UP II-KO 
mice, UP Ia remains trapped in the ER [9].
UP EXPRESSION IN CELL LINES
Cultured urothelial cells can synthesize the UPs, but the UPs do 
not assemble into two-dimensional crystals [36]. Thus, cultured 
bovine urothelial cells still synthesize large amounts of the UPs, 
although they almost completely lack the cytoplasmic (fusiform) 
vesicles that are prominent cellular structures in mature um-
brella cells in vivo and which are presumably involved in deliv-
ering the UPs to the apical surface [36,37]. Moreover, the apical 
surface of these cultured urothelial cells completely lack the 
two-dimensional crystals of 16 nm uroplakin particles [20,36, 
37]. The inability of regenerating urothelial cells to assemble 
Table 1. Uroplakin mRNA expression in various tissues from 
expressed sequence tag (EST) 
Gene 
Genbank
code  Code type 
Characteristics of EST 
expression 
Uroplakin Ia  NM026815.2  Reference  
  RNA 
Urinary bladder 
DV043876  EST  Prostate pool,  
  10 day old male mice 
DV048517  EST  Prostate pool,  
  35 day old male mice 
BX517024  EST  Uterus, adult 
AI225453  EST  Uterus, adult 
DV074433  EST  Prostate, ventral prostate 
DV074432  EST  Prostate, ventral prostate 
Uroplakin Ib  NM178924  Reference  
  RNA 
Urinary bladder 
BQ892200  EST  Olfactory epithelium 
CF586524  EST  Pancreas 
BB653177  EST  Hippocampus, adult mice 
CK627789  EST  Whole eye 
BB530943  EST  Lung, neonate 
DV068933  EST  Prostate (pooled  
  urogenital sinuses) 
DV552492  EST  Total cornea, adult 
CK922053  EST  Thyroid 
BB665799  EST  Oviduct,  
  2 days pregnant mice 
CF586523  EST  Pancreas 
BY367830  EST  Spleen, neonate 
BB219662  EST  Aorta and vein, adult male 
Uroplakin II  NM009476  Reference  
  RNA 
Urinary bladder 
CX565093  EST  Whole eye 
Uroplakin III  AF222750  Reference  
  RNA 
Urinary bladder 
CB598360  EST  Lung and heart 
BX512009  EST  Mammary gland 
BB605052  EST  Lung, neonate 8    www.einj.org
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plaques could be functionally important, because a cell surface 
laden with the rigid-looking plaques may be incompatible with 
cell migration and proliferation during wound repair [20]. The 
RT4 cell line, derived from a grade 1 transitional cell carcinoma 
(TCC), can form a well differentiated stratified urothelium when 
seeded onto a stroma. This suggests that the RT4 cell line will 
be invaluable as a model for urothelial cytodifferentiation and 
for studying the differential regulation and expression of the 
UP genes. The expression of the UP Ia and UP II genes remains 
highly differentiation restricted in superficial TCC. The genes 
are expressed by the luminal cells of well-differentiated papillae, 
but the expression is lost from histologically less differentiated 
areas (Table 2) [38]. 
KNOCKOUT MICE
KO mice are genetically engineered mice in which a target gene 
or genes have been turned off through a targeted mutational 
method. For this reason, the UP KO mice are important animal 
models for studying the roles of UP genes. With KO mice of 
UP II or III, the incorporation of fully assembled UP proteins 
into the apical surface through fusion of the fusiform vesicles 
with the apical membrane was shown to play a role in the main-
tenance of the urothelial barriers [9,39].
  In UP II KO mice, protein levels of UP Ia, UP Ib, and UP III 
are reduced 10–20-fold compared with those of the normal 
control mice. However, the mRNA levels of UP Ia and UP III 
are up-regulated twofold, whereas that of UP Ib is up-regulated 
by 10–20-fold in a compensatory manner [9]. In addition, the 
UP-delivering fusiform vesicles are totally replaced by numer-
ous small, spherical vesicles [9]. In UP II–deficient urothelium, 
although the UP Ib/III pair can be delivered to the apical sur-
face and the small vesicles (150–200 nm in diameter) accumu-
late in the UP II-deficient superficial cells, the UP Ib/ III pair by 
itself cannot form the 16-nm particle, let alone the urothelial 
plaques. This leads to the entrapment of UP Ia in the ER, but al-
lows the remaining UP Ib/III pair to reach the apical urothelial 
surface [9]. No 16-nm particle or apical plaques are formed. 
Some breeding pairs of UP II-deficient mice reproducibly die 8 
to 10 days postnatally as a result of renal failure. It seems that 
major UP defects may cause urinary tract anomalies that, in se-
vere cases, could lead to death. In addition, the levels of many 
urinary components, including uric acid, creatinine, potassium, 
sodium, and chloride ions, were slightly reduced, possibly be-
cause of defects in mechanisms of urine concentration in UP II 
KO mice. The concentration of blood urea nitrogen also almost 
doubled, suggesting a compromised renal function [9]. 
  These results highlight the critical functional importance of 
UPs in the formation of a specialized urothelial apical surface. 
Serial sectioning of the urinary tracts from surviving UP II 
knockout mice reveal areas of the ureter with epithelial polyps 
or complete epithelial occlusion, which causes structural ob-
struction [9]. In addition, increased bladder capacity, micturi-
tion pressure, and demonstrable nonvoiding contractions are 
observed in male UP II KO mice compared with normal mice 
[40]. 
  The detergent-insoluble membrane fraction of the UP III-
deficient mouse urothelium shows a significantly reduced num-
ber of UPs, whereas that of the UP II-deficient urothelium con-
tains almost no detectable UPs. Together, these results indicate 
that UP II ablation completely abolishes plaque formation. Be-
cause both heterodimers (Ia/II and Ib/IIIa) are required for 
normal plaque formation, it has been postulated that UP IIIb 
replaces the necessary function of the UP IIIa to form the Ib/
IIIb heterodimer, allowing for the small crystal plaques to de-
velop. Again, knockout of UP II, which does not have a known 
isoform, leads to the complete absence of plaque formation, 
supporting the idea that the two UP heterodimers are both crit-
ical for plaque formation [9].
  In the ablation of UP III, abnormal synthesis and processing 
of UP Ib, i.e., the level of UP Ib mRNA is greatly increased, 
whereas the amount of UP Ib protein is reduced [39]. These 
mice also have a reduced urothelial plaque size, compromised 
Table 2. Expression of uroplakin transcripts by normal and tu-
mor-derived urothelial cell lines by ribonuclease protection as-
say
Cell line Pathology Origin UP Ia UP Ib UP II UP III    
RT4 Papilloma Urinary 
  bladder
2+ 3+ 3+ 2+
RT112 Carcinoma Urinary 
  bladder
N 3+ N N
HT1376 Carcinoma Urinary 
  bladder
N 3+ N N 
Colo232 Carcinoma Urinary 
  bladder
N N N N 
KK47 Carcinoma Urinary 
  bladder
N N N N 
VM-CUB-3 Carcinoma Urinary 
  bladder
2+ 3+ 2+ N
N, negative expression.www.einj.org    9
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urothelial permeability barrier function, and retrograde flow of 
urine from the bladder into the ureters (vesicoureteral reflux), 
resulting in hydronephrosis [3,39]. These results establish that 
UP III is an integral subunit of urothelial plaques, which con-
tribute to the permeability barrier function of the urothelial 
apical surface, and suggest that urothelial defects may play a 
role in vesicoureteral reflux (VUR) [3,39]. The inactivation of 
the mouse UP III gene results in VUR and hydronephrosis rais-
es the possibility that UP defects may cause VUR in humans 
[39,41]. 
  The spontaneous bladder contraction activity value for all 
male and female UP KO mice is signiﬁcantly greater than that 
observed in the wild-type mice [40]. Furthermore, the UP II 
KO mice display signiﬁcant elevations in spontaneous activity, 
intermicturition pressure, and micturition pressure relative to 
both the wild-type and UP IIIa KO mice [40]. The UP IIIa KO 
mice, in turn, have lower basal pressure and threshold pressure 
values than do either the UP II or wild-type mice [40]. Cysto-
metric records from both UP II and UP IIIa KO mice (both 
males and females) reveal demonstrable nonvoiding contrac-
tions (i.e., detrusor overactivity ) [40]. Interestingly, the observed 
detrusor overactivity is more pronounced in the UP II KO mice 
than in the UP IIIa KO mice [40].  
CHANGES IN UP EXPRESSION IN THE 
URINARY BLADDER AFTER 
CYCLOPHOSPHAMIDE TREATMENT
The turn-over and differentiation of urothelial cells in the nor-
mal urothelium is very slow, and their life span is very long 
making it difficult to study the detailed sequence of differentia-
tion stages in normal urothelium [42]. However, the turn-over 
or repair process in the urothelium after chemical insult is very 
rapid. This dynamic process can help us to understand the patho-
physiological mechanisms of the UPs in the urinary bladder. In 
addition, because chemicals such as cyclophosphamide are well 
known to induce interstitial cystitis and hemorrhagic cystitis in 
animal models, it is a highly reasonable approach to determine 
the role of UPs in the urothelium by applying the cyclophos-
phamide-induced animal model.
  Cyclophosphamide causes mucosal ulceration, transmural 
edema and epithelial necrosis that are associated with acute 
hemorrhage (Fig. 7) [43,44]. At 24 hours after cyclophospha-
mide exposure, the superficial epithelium is detached and in-
termediate cells are exposed (Fig. 8). The regeneration process 
is started immediately and is completed within 2 weeks after 
cyclophosphamide injection [27]. Various stages of urothelial 
differentiation accompany the regeneration. This is reflected in 
the successive appearance of microvilli and ropy ridges on the 
apical surface of the superficial cells [27]. The level of all UP 
mRNAs, the protein expression of UP II and IIIa by immunob-
lotting study, and the expression of UP IIIa by immunolocaliza-
tion study are maximally suppressed within 12 hours; this par-
200 μm
Fig. 8. Structural analysis of rat urothelium after 24-hour expo-
sure to 150 mg cyclophosphamide. There are clear-cut areas that 
are denuded of umbrella cells and intermediate cells can be dis-
cerned. Arrows indicate denuded areas.
Fig. 7. Histological alterations in the cyclophosphamide-induced 
rat bladder. (A) normal epithelium projected to bladder lumen 
in controls (H&E, ×40). (B) histologic section of the urinary 
bladder of mice showing epithelial ulceration, hemorrhage, and 
submucosal edema at 12 hours after cyclophosphamide injection 
(H&E, ×10). (C) and (D), cystitis improved at 24 and 72 hours, 
respectively (H&E, ×10) (Reprinted from Choi SH et al. J Kore-
an Med Sci 2009;24:684-9, with permis  sion of Korean Academy 
of Medical Sciences) [43].
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tially recovers at 24 hours and completely recovers at 72 hours 
following cyclophosphamide injection in the mouse bladder. 
Even though a large area of urothelium is lost after cyclophos-
phamide injection, some focal areas of intact uroepithelium 
show a significant reduction of UP III expression on immuno-
histochemical staining. It seems that cyclophosphamide may 
actively depress the expression of UPs in uroepithelium when 
they are damaged by cyclophosphamide (Fig. 9) [43]. These re-
sults suggest that rapid resealing of injuries to the bladder per-
meability barrier is of major physiological importance for re-
storing the protection ability of the bladder. 
  Vigorous diuresis and agents that can detoxify cyclophospha-
mide, such as 2-mercaptoethene sulfate (MESNA), have been 
used to decrease urotoxicity [44]. However, MESNA-treated rats 
reveal transient and early reductions in the mRNA levels of all 
UPs [44]. That finding suggests that MESNA treatment may 
partially preserve the UP expression of mRNA and protein in 
cyclophosphamide-induced urinary bladder epithelium. In ad-
dition, the responses in the level of UPs against cyclophospha-
mide insult are heterogeneous (i.e., markedly suppressed in UP 
II and lesser destructive in UP III) [44]. These findings can ex-
plain the fact that the bladder protection is not always achieved 
even after the prophylactic use of MESNA.
  In conclusion, signiﬁcant progress has been made in the 
characterizations of UPs in genitourinary tract diseases. As a 
result, it is generally accepted that UPs are actively involved in 
creating the blood-urine barrier and in urothelial differentia-
tion, trafficking, and genitourinary development in animal 
models. Lessons from this basic research can lead to an under-
standing of the clinical significance of the UPs. Urothelial dam-
age and vesical dysfunction in humans can be caused by inter-
stitial cystitis, bladder outlet obstruction, and overactive blad-
der, as well as vesicoureteral reflux and kidney development. 
Studies of UPs expression and major UP genetic mutations can 
explain or help in our understanding of the mechanisms of the 
above lower urinary tract diseases. In the near future, some 
pharmacotherapies involving UPs may lead to large clinical 
benefits in the treatment of genito-urinary diseases. 
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